Dossier assessment

Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-136
Last updated

Report documents

  1. Extract of dossier assessment

    Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 285 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-136_en
  2. Dossier assessment

    Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 652 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-136

Dossier assessment

Indication:

Paediatric patients 8 years of age and older with heterozygous familial hypercholesterolaemia

Result of dossier assessment:
  • Patients in whom dietary and drug options for lipid lowering have not been exhausted: added benefit not proven
  • Patients in whom dietary and drug options for lipid lowering have been exhausted: added benefit not proven

Project details

Project no.
A23-136
Commission
Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-136_en

Connected Projects

  1. Dossier assessment

    Alirocumab - Benefit assessment according to §35a Social Code Book V

    Project no.
    A15-47
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form